gwas of diabetic nephropathy is the genie out of the bottlegwas的糖尿病肾病是精灵放出魔瓶的.pdfVIP

Perspective GWAS of Diabetic Nephropathy: Is the GENIE out of the Bottle? ¨ 1 2 Carsten A. Boger *, John R. Sedor 1 Department of Internal Medicine II (Nephrology), University Medical Center Regensburg, Regensburg, Germany, 2 Department of Medicine and Department of Physiology and Biophysics, Case Western Reserve University and the Rammelkamp Center for Research and Education, MetroHealth System campus, Cleveland, Ohio, United States of America Diabetic nephropathy (DN) is associated lying pathomechanisms: ESRD as the the lack of significant association in replica- with excess morbidity and mortality, in extreme form of reduced kidney function tion analysis calls for independent confirma- both type 1 (T1D) and type 2 (T2D) (glomerular filtration rate, GFR), and mac- tion of this locus in other studies before its diabetic patients. Despite intensification of roalbuminuria reflecting severe glomerular implications for DN mechanisms can be treatment, DN remains a growing prob- filtration barrier dysfunction. Since these drawn. lem worldwide [1–6]. In 2009, treatment two traits have distinct genetic underpin- So—does this publication really let the of diabetic end stage renal disease patients nings [11–16], the authors refined their DN ‘‘GENIE’’ for DN gene discovery out of the accounted for approximately 40% of the case definition to include only diabetic bottle, discovering at last the definitive ‘‘DN US$43 billion expended for dialysis treat- ESRD patients, which were contrasted with gene(s)’’—or is this merely wishful thinking? ment in the United States all o